Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-023970
Filing Date
2025-08-14
Accepted
2025-08-14 16:02:26
Documents
44
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 530445
2 EX-31.1 ex31-1.htm EX-31.1 17054
3 EX-31.2 ex31-2.htm EX-31.2 17073
4 EX-32.1 ex32-1.htm EX-32.1 8113
  Complete submission text file 0001641172-25-023970.txt   3089570

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE telo-20250630.xsd EX-101.SCH 22350
6 XBRL CALCULATION FILE telo-20250630_cal.xml EX-101.CAL 25654
7 XBRL DEFINITION FILE telo-20250630_def.xml EX-101.DEF 99574
8 XBRL LABEL FILE telo-20250630_lab.xml EX-101.LAB 213084
9 XBRL PRESENTATION FILE telo-20250630_pre.xml EX-101.PRE 172825
46 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 381999
Mailing Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131
Business Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131 786-396-6723
Telomir Pharmaceuticals, Inc. (Filer) CIK: 0001971532 (see all company filings)

EIN.: 872606031 | State of Incorp.: FL | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41952 | Film No.: 251218525
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)